[Form 4] BridgeBio Oncology Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 disclosing that Eli M. Wallace, who serves as Chief Executive Officer and a director, was granted a stock option on 10/02/2025. The option covers 1,614,400 shares of common stock with an exercise price of $12.44 per share and an expiration date of 10/01/2035. The option becomes exercisable in equal monthly installments equal to 1/48th of the total award, beginning on 10/02/2025, subject to continued service. The reporting person is shown as the direct holder of the option and the Form 4 was signed by an attorney-in-fact on 10/06/2025.

Positive

• 1,614,400 option grant aligns CEO incentives with long-term shareholder value
• Monthly vesting (1/48th) encourages continued service and reduces immediate concentration of exercisable options
• 10-year term (expiration 10/01/2035) gives flexibility for long-term value realization

Negative

• Potential dilution if a large portion of 1,614,400 options are exercised over the vesting period
• Immediate exercisability is limited, but future concentrated exercises could pressure share supply when vested tranches become exercisable

Insights

Compensation Analyst

Large long-dated option award with time-based monthly vesting.

The grant of 1,614,400 stock options at an exercise price of $12.44 creates a long-term equity stake tied to share-price appreciation before the 10/01/2035 expiration. Monthly vesting in 1/48th installments starting 10/02/2025 aligns exercise opportunity with continued service over four years.

This structure reduces short-term exercise risk but concentrates potential dilution if a large tranche becomes exercisable; monitor the companywide share pool and outstanding options to quantify dilution over the vesting period, particularly through the next 12 months.

Corporate Governance Analyst

CEO award signals alignment but raises governance and disclosure considerations.

The filing shows the CEO is both an officer and director and holds the option directly, which is standard for executive equity compensation. The clear monthly vesting schedule provides transparency on when shares may hit the market if exercised.

Key items to watch are any subsequent sales or exercises reported on future Forms 4 and how this award interacts with company equity plan limits and shareholder-approved authorization within the next 1–4 years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wallace Eli M.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	10/02/2025		A		1,614,400		(1)	10/01/2035	Common Stock	1,614,400	$0	1,614,400	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Aaron Chan, Attorney-in-Fact	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for BBOT disclose about Eli M. Wallace?

The Form 4 shows a grant of a stock option covering 1,614,400 shares with an exercise price of $12.44, exercisable monthly in 1/48th increments starting 10/02/2025 and expiring 10/01/2035.

When do the options become exercisable for the BBOT CEO?

Vesting begins on 10/02/2025 with monthly vesting equal to 1/48th of the total award, subject to continued service.

What is the exercise price and expiration date of the awarded options?

The exercise price is $12.44 per share and the options expire on 10/01/2035.

Who signed the Form 4 and when was it filed?

The Form 4 bears the signature of an attorney-in-fact, Aaron Chan, dated 10/06/2025.

Does the Form 4 indicate indirect ownership or third-party arrangements?

The filing lists the ownership form as Direct for the reported 1,614,400 options; no indirect ownership or third-party arrangements are disclosed.